LAG-3 Targeted Drug Development Summit

LAG-3 Targeted Drug Development Summit
January 25-27, 2022 – Online

With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.

Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit (January 25-27, 2022) is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.

Ensure your LAG-3 program reaches full clinical potential through hearing from experts discuss the progress that has been made and challenges faced in bispecific antibody based approaches:

-Improving combination therapy regimens

-Better understanding the underpinning biology of LAG-3 as a cancer target

-Utilizing biomarkers to understand the interplay between PD-1 and LAG-3

Join translational and clinical experts in LAG-3 development from Roche, BMS, F-STAR, Regeneron, Immutep, Macrogenics, University of Pittsburgh and more.

MabDesign members benefit of 10% discount with exclusive code: MAD10

 

S'inscrire

Date

January 25-27 2022

Lieu

Online

Organisateur

Hanson Wade

Prix

MabDesign Members benefit from 10% off with code MAB10